{"description":"Impression cytology or superficial keratectomy procedure (ICSK) population included participants from all-treated population who had a tissue sample collected using IC or SK procedure, whether or not the specimen is evaluable.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"A superficial corneal epithelial tissue specimen was obtained by performing impression cytology (IC) procedure in participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. The procedure was only performed in one eye. Participants did not need to be on active treatment.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Participants Allocated to Undergo Impression Cytology Procedure"},{"deathsNumAffected":0,"deathsNumAtRisk":3,"description":"A superficial corneal epithelial tissue specimen was obtained by performing superficial keratectomy (SK) procedure in participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. The procedure was only performed in one eye. Participants did not need to be on active treatment.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Participants Allocated to Undergo Superficial Keratectomy Procedure"}],"frequencyThreshold":"0","timeFrame":"All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to approximately 23 months."}